Literature DB >> 10627642

Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation.

P Mehta1, S Beltz, A Kedar, J Graham-Pole, J R Wingard.   

Abstract

The pharmacokinetics of tacrolimus have been studied in healthy volunteers and in adults undergoing bone marrow transplantation. However, there is little information on the pharmacokinetics of tacrolimus in children undergoing BMT. We studied pharmacokinetics of tacrolimus in seven patients (age 8-17 years) undergoing allogeneic stem cell transplantation. Four patients received matched unrelated donor (MUD) transplants, two underwent HLA-matched related donor transplants, and one underwent an umbilical cord blood donor transplant. All patients received tacrolimus by continuous infusion at 0.03-0.04 mg/kg/day beginning on the day prior to transplant. Tacrolimus whole blood concentrations were monitored by microparticle enzyme immunoassay. Our goal was to maintain a blood tacrolimus level of 10-20 microg/ml. Once patients were tolerating oral medications, tacrolimus infusion was converted to oral dosing using a 4:1 conversion. Dose of tacrolimus and resulting tacrolimus concentrations were recorded and the total body clearance of tacrolimus was calculated retrospectively. The mean clearance, based on first steady-state tacrolimus concentrations necessary for achieving a therapeutic level (10-20 microg/ml), was 108.1 ml/h/kg (range 79.7-142.0 ml/h/kg), greater than that reported in adult BMT patients (71 +/- 34 ml/h/kg). The average dose required to achieve that therapeutic range was 0.0354 mg/kg/day as an intravenous continuous infusion. Over the entire course of intravenous tacrolimus, mean clearance was 97.0 ml/h/kg (range 33.4-153.3 ml/h/kg). In six of the seven patients, clearance values dropped after 2-4 weeks of therapy by an average of 32.5 ml/h/kg. In two patients, sharp drops in clearance were temporally related to changes in liver function tests. Three of the seven patients died of severe acute GVHD; all these had undergone matched unrelated donor transplantation, and two of these three had initial clearance levels over 120 ml/h/kg. Thus, children appear to have more rapid tacrolimus clearance than adults and may need to begin therapy earlier in order to obtain stable and optimal levels. More studies are needed to confirm these preliminary results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10627642     DOI: 10.1038/sj.bmt.1702053

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.

Authors:  Violette Gijsen; Seema Mital; Ron H van Schaik; Offie P Soldin; Steven J Soldin; Ilse P van der Heiden; Irena Nulman; Gideon Koren; Saskia N de Wildt
Journal:  J Heart Lung Transplant       Date:  2011-09-17       Impact factor: 10.247

Review 2.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients.

Authors:  Xiao-Lin Liu; Yan-Ping Guan; Ying Wang; Ke Huang; Fu-Lin Jiang; Jian Wang; Qi-Hong Yu; Kai-Feng Qiu; Min Huang; Jun-Yan Wu; Dun-Hua Zhou; Guo-Ping Zhong; Xiao-Xia Yu
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

Review 5.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Michelle Kolb; Katharine Offer; Zhezhen Jin; Justine Kahn; Monica Bhatia; Andrew L Kung; James H Garvin; Diane George; Prakash Satwani
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-13       Impact factor: 5.742

Review 7.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 8.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  The effectiveness of tacrolimus and minidose methotrexate in the prevention of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in children: a single-center study in Korea.

Authors:  Seong Shik Park; So Eun Jun; Young Tak Lim
Journal:  Korean J Hematol       Date:  2012-06-26

10.  Phenytoin and Rifampin Do Not Decrease Levels in Acute Tacrolimus Toxicity.

Authors:  Benjamin O Lawson; Heemesh Seth; Dan Quan
Journal:  J Investig Med High Impact Case Rep       Date:  2018-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.